HeyJaredLiam Davenport
- Indexed articles, last 90 days
- 1
- Latest publication
- Jul 7, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 7, 2026
Latest articles
Q&A: Managing GI Toxicities of Immunotherapy (opens the original)
Read excerpt
Immune checkpoint inhibitors (ICIs) have been transformative in the treatment of certain cancers, but as use of the drugs continues to climb, so do the ranks of patients dealing with gastrointestinal (GI) side effects. GI adverse events, including inflammatory conditions of the colon, liver, stomach, pancreas, and gallbladder, affect up to 40% of patients on ICIs. They’re also among the most common grade 3 or higher adverse events experienced with the drugs. “This underlies the importance of set
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.